

# Laquisa C Hill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9242705/publications.pdf>

Version: 2024-02-01

21  
papers

287  
citations

1040056

9  
h-index

940533

16  
g-index

22  
all docs

22  
docs citations

22  
times ranked

463  
citing authors

#	ARTICLE	IF	CITATIONS
1	Beyond CD19 CAR-T cells in lymphoma. <i>Current Opinion in Immunology</i> , 2022, 74, 46-52.	5.5	3
2	COVID-specific T's may offset therapeutically endangered B's. <i>Blood</i> , 2022, 139, 12-13.	1.4	1
3	Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	2
4	Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL. <i>Blood</i> , 2022, 139, 2706-2711.	1.4	13
5	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. <i>Blood</i> , 2022, 140, 16-24.	1.4	14
6	Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. <i>Blood</i> , 2021, 137, 2585-2597.	1.4	38
7	Health disparities experienced by Black Americans with multiple myeloma in the United States: A population-based study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18512-e18512.	1.6	0
8	Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. <i>Leukemia and Lymphoma</i> , 2021, 62, 3256-3263.	1.3	11
9	Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 785.e1-785.e6.	1.2	2
10	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. <i>Blood</i> , 2021, 138, 471-471.	1.4	0
11	Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 654-654.	1.4	9
12	37. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T Cells Demonstrate Reactivity Against Emerging Variant Strains. <i>Open Forum Infectious Diseases</i> , 2021, 8, S27-S27.	0.9	3
13	CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S237.	2.0	12
14	Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19525-e19525.	1.6	0
15	A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4622-4622.	1.6	9
16	Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19. <i>Blood</i> , 2020, 136, 5-5.	1.4	2
17	CAR-T cell therapy for non-Hodgkin lymphomas: A new treatment paradigm. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e54.	0.9	8
18	Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies. <i>Blood</i> , 2019, 134, 199-199.	1.4	53

#	ARTICLE	IF	CITATIONS
19	T Cell Immunity Toward Viral- and Tumor-Antigens Is Preserved in MDS Patients. Blood, 2019, 134, 4225-4225.	1.4	0
20	New and emerging therapies for acute and chronic graft-versus-host disease. Therapeutic Advances in Hematology, 2018, 9, 21-46.	2.5	90
21	The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2018, 16, 375-386.	0.3	15